Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...

Tirzepatide is part of a class of drugs known as dual GIP/GLP-1 receptor agonists. These act on hormones involved in the ...

Novo Nordisk owns two of them ... for when it gets FDA approval to sell VK2735 in pill form. Viking told investors that this agreement "provides Viking with sufficient long-term supply of both ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

At the pace with which the proportion of overweight people is growing, half of Nepal’s adult population will be obese by 2050 ...